Scancell Holdings plc (SCNLF)

USD 0.18

(0.0%)

Market Cap (In USD)

186.62 Million

Revenue (In USD)

5.27 Million

Net Income (In USD)

-11.93 Million

Avg. Volume

164.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.1255-0.2335
PE
-
EPS
-
Beta Value
0.451
ISIN
GB00B63D3314
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Prof. Lindy Gillian Durrant Ph.D.
Employee Count
-
Website
https://www.scancell.co.uk
Ipo Date
2013-08-02
Details
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.